Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
作者： Brigitte Rack , Julia Jückstock , Maria Günthner-Biller , Ulrich Andergassen , Julia Neugebauer
DOI: 10.1007/S00404-011-1954-2
关键词: Bone marrow 、 Antibody 、 Breast cancer 、 Trastuzumab 、 Internal medicine 、 Isolated Tumor Cells 、 HER2/Neu Positive 、 Minimal residual disease 、 Monoclonal 、 Oncology 、 Medicine
摘要: Purpose Isolated tumor cells (ITC) in the bone marrow of breast cancer patients increase risk recurrence and decrease survival, both at primary diagnosis during follow-up. We tested efficacy trastuzumab clearing HER2/neu-positive ITC from completing treatment.
springer.com
sci-hub.se 参考文章(36)
Gert Riethmüller, Christina R. M. Kentenich, Wolfgang Janni, Florian Hepp, Klaus Pantel, Harald L. Sommer, Fritz Willgeroth, Stephan Braun, Monoclonal Antibody Therapy with Edrecolomab in Breast Cancer Patients: Monitoring of Elimination of Disseminated Cytokeratin-positive Tumor Cells in Bone Marrow Clinical Cancer Research. ,vol. 5, pp. 3999- 4004 ,(1999)
A Vincent-Salomon, JY Pierga, J Couturier, CD d'Enghien, C Nos, B Sigal-Zafrani, M Lae, P Freneaux, V Dieras, JP Thiery, X Sastre-Garau, None, HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? British Journal of Cancer. ,vol. 96, pp. 654- 659 ,(2007) , 10.1038/SJ.BJC.6603584
C. A. Klein, O. Schmidt-Kittler, J. A. Schardt, K. Pantel, M. R. Speicher, G. Riethmuller, Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 4494- 4499 ,(1999) , 10.1073/PNAS.96.8.4494
Julian A. Schardt, Manfred Meyer, Claudia H. Hartmann, Falk Schubert, Oleg Schmidt-Kittler, Christine Fuhrmann, Bernhard Polzer, Marco Petronio, Roland Eils, Christoph A. Klein, Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. ,vol. 8, pp. 227- 239 ,(2005) , 10.1016/J.CCR.2005.08.003
Wolfgang Janni, Florian Hepp, Dorothea Rjosk, Christina Kentenich, Barbara Strobl, Christian Schindlbeck, Peer Hantschmann, Harald Sommer, Klaus Pantel, Stephan Braun, The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer. ,vol. 92, pp. 46- 53 ,(2001) , 10.1002/1097-0142(20010701)92:1<46::AID-CNCR1290>3.0.CO;2-6
E Solomayer, G Gebauer, P Hirnle, W Janni, H Lück, S Becker, J Huober, B Kraemer, B Wackwitz, T Fehm, Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Research. ,vol. 69, pp. 2048- ,(2009) , 10.1158/0008-5472.SABCS-2048
Marta Pestrin, Silvia Bessi, Francesca Galardi, Mara Truglia, Annibale Biggeri, Chiara Biagioni, Silvia Cappadona, Laura Biganzoli, Augusto Giannini, Angelo Di Leo, Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients Breast Cancer Research and Treatment. ,vol. 118, pp. 523- 530 ,(2009) , 10.1007/S10549-009-0461-7
Erich F. Solomayer, Sven Becker, Graziella Pergola-Becker, Robert Bachmann, Bernhard Krämer, Ulrich Vogel, Hans Neubauer, Diethelm Wallwiener, Jens Huober, Tanja N. Fehm, Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients Breast Cancer Research and Treatment. ,vol. 98, pp. 179- 184 ,(2006) , 10.1007/S10549-005-9147-Y
Kan Yonemori, Koji Tsuta, Chikako Shimizu, Yutaka Hatanaka, Kaoru Hashizume, Makiko Ono, Yukihiro Nakanishi, Tadashi Hasegawa, Yasuji Miyakita, Yoshitaka Narita, Soichiro Shibui, Yasuhiro Fujiwara, Immunohistochemical profiles of brain metastases from breast cancer Journal of Neuro-Oncology. ,vol. 90, pp. 223- 228 ,(2008) , 10.1007/S11060-008-9654-X
Julie E. Lang, Kailash Mosalpuria, Massimo Cristofanilli, Savitri Krishnamurthy, James Reuben, Balraj Singh, Isabelle Bedrosian, Funda Meric-Bernstam, Anthony Lucci, HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Research and Treatment. ,vol. 113, pp. 501- 507 ,(2009) , 10.1007/S10549-008-9951-2